Tianeptine

From Self-sufficiency
Revision as of 11:10, 20 September 2010 by Jontas (Talk | contribs) (1 revision)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Tianeptine
File:(±)-Tianeptine Structural Formulae V.1.svg
File:Tianeptine3d.png
Systematic (IUPAC) name
(RS)-7-(3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-ylamino)heptanoic acid S,S-dioxide
Clinical data
Routes of
administration		 Oral
Legal status
Legal status
  • ℞ (Prescription only)
Pharmacokinetic data
Bioavailability 70-99%[1]
Metabolism Hepatic
Biological half-life 2.5 hours[1]
Excretion Renal[1]
Identifiers
CAS Number 66981-73-5
ATC code N06AX14 (WHO)
PubChem CID 68870
Chemical data
Formula C21H25ClN2O4S
Molar mass 436.953 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.
Coaxil redirects here. For the transmission line for radio frequency signals, see Coaxial cable.

Tianeptine (INN) (Stablon, Coaxil, Tatinol) is a selective serotonin reuptake enhancer (SSRE) drug used for treating major depressive episodes (mild, moderate, or severe). Unlike conventional tricyclic antidepressants, tianeptine enhances the reuptake of serotonin instead of inhibiting it, opposite to the action of SSRIs. Moreover, it enhances the extracellular concentration of dopamine in the nucleus accumbens[2] and modulates the D2 and D3 dopamine receptors.[3] There is also action on the NMDA and AMPA receptors.

Tianeptine, indicated as a thymoleptic, reduces the effects of serotonin in the limbic system and the pre-frontal cortex, giving rise to a mood elevation, unlike the mood blunting associated with SSRIs. Like SSRIs, however, tianeptine's onset-of-action delay is approximately 2–6 weeks with improvements sometimes noticeable in as soon as one week.

Its short-lived, but pleasant, stimulant effect experienced by some patients is shared with its predecessor, amineptine, whose side effects related to dopamine uptake inhibitor activity resulted in Servier's research into tianeptine.[citation needed] Suggested dosage is three times daily, due to its short duration of action.

Tianeptine has strong antidepressant and anxiolytic properties with a relative lack of sedative, anticholinergic and cardiovascular adverse effects, thus suggesting it is particularly suitable for use in elderly patients and in those following alcohol withdrawal; such patients can be more sensitive to the adverse effects of psychotropic drugs.[4]

Recent interesting results indicate anticonvulsant and analgesic activity of tianeptine and its possible interaction with adenosine A1 receptors.[5]

Currently, Tianeptine is approved in France and manufactured and marketed by Laboratoires Servier SA; it is also marketed in a number of other European countries under the trade name "Coaxil" as well as in Asia and Latin America as "Stablon" and "Tatinol" but it is not available in the UK.

Uses

Approved

Tianeptine shows efficacy against serious depressive episodes (major depression), comparable to amitriptyline, imipramine and fluoxetine, but with far fewer side effects. It was shown to be more effective than maprotiline in a group of patients with co-existing depression and anxiety. Tianeptine also displays significant anxiolytic properties and is useful in treating a spectrum of anxiety disorders including panic disorder, as evidenced by a study in which those administered 35% CO2 gas (carbogen) on paroxetine (Paxil) or tianeptine (Stablon) therapy showed equivalent panic-blocking effects.[6]

Investigational and ongoing research

Tianeptine has been reported to be very effective for asthma starting in August 1998, when Dr. Fuad Lechin and colleagues at the Central University of Venezuela Institute of Experimental Medicine in Caracas published the results of a 52-week randomized controlled trial of asthmatic children; the children in the groups that received tianeptine had a sharp decrease in clinical rating and increased lung function.[7] Two years earlier, they had found a close, positive association between free serotonin in plasma and severity of asthma in symptomatic patients.[8] As tianeptine was the only agent known to both reduce free serotonin in plasma and enhance uptake in platelets, they decided to use it to see if reducing free serotonin levels in plasma would help.[7] By November 2004, there had been two double-blind placebo-controlled crossover trials, and a 25,000+ patient open-label study lasting over seven years, all showing effectiveness.[9] A 2005 study in Egypt demonstrated tianeptine to be effective in men with depression and erectile dysfunction.[10] Tianeptine also has anticonvulsant and analgesic effects,[5] and a clinical trial in Spain that ended in January 2007 has shown that tianeptine is effective in treating pain due to fibromyalgia.[11][12] Tianeptine is also being studied in the treatment of ADD/ADHD.

It is currently being researched for its effectiveness in irritable bowel syndrome.[13]

Tinaneptine has been found to be effective in depression in Parkinson's disease[14] and in post-traumatic stress disorder[15] of which it was as safe and effective as fluoxetine (Prozac, an SSRI) and moclobemide (Aurorix, an MAO-A inhibitor).[16]

Contraindications

According to Servier International, tianeptine is contraindicated in children under 15 years of age, people taking MAOIs, and pregnant or lactating women.[17] However, as of 2005, there are no studies published showing increased risk of birth defects.[18]

File:StablonBox.jpg
Stablon box and blister pack.

Side effects

Tianeptine was both studied for short-term (3 month) and long-term treatment (12 months) and equally well tolerated. The studies encompassed 1,300 to nearly 3,000 patients each.

Side effects are as follows (amitriptyline vs tianeptine):

Costa e Silva and colleagues at the Jardim Botanico in Rio de Janeiro, Brazil reported a greater frequency of headaches in the tianeptine group as compared with placebo.[19]

Sema Gülen Yıldırım and colleagues reported in 2004 of a case of hypomania caused by tianeptine.[20]

Interestingly, tianeptine along with its two metabolites (S8849, S3139) does not affect the reuptake of monoamines (DA, 5-HT, and noradrenaline) in vitro. Results from in vivo studies confirm that serotonin reuptake is enhanced — while dopamine and noradrenaline are unaffected — suggesting a mechanism independent of SERT.[21] No data is available regarding effects of the drug on postsynaptic receptors.

Usual doses

The recommended dosage is three tablets daily, one in the morning, one at midday, and one in the evening before the main meals of the day. In chronic alcoholics, whether cirrhotic or not, no alteration of dosage is necessary. In subjects over 70 years of age, and in subjects with renal insufficiency, the dosage should be restricted to two tablets per day.[22]

Coping with suicide risks

As is generally true for activating/nonsedating antidepressants, particularly agitated patients or those developing increase of energy together with suicidal thoughts before remission occurs will normally need initial comedication (1 to 4 weeks) with an effective sedating drug such as a benzodiazepine, barbiturate or neuroleptic. Additionally, hospitalisation of these patients is desirable (close observation possible). These measures to lower the risk of suicide should be continued until remission of depression is stable.

Abuse and addiction potential

Abuse of tianeptine is rare and thus far has only been seen in patients with pre-existing multi-substance abuse disorders. 141 cases of abuse were identified between 1989 and 2004, correlating to an incidence of 1 to 3 cases per 1000 patients treated with tianeptine. The main reason for abuse is to achieve an anxiolytic effect. According to Servier, cessation of treatment with tianeptine is difficult, due to the possibility of withdrawal symptoms in a patient.[23][24]

One patient reportedly consumed a total of 240 12.5 mg tablets (3000 mg) per day for several months and was later successfully detoxified in an inpatient setting. The report indicated that a tolerance was developed and there were physical withdrawal symptoms.[25]

In 2007, according to French Health Products Safety Agency (Agence française de sécurité sanitaire des produits de santé), tianeptine's manufacturer Servier agreed to modify the drug's label, following problems with dependency.[26]

Singapore's Ministry of Health has restricted the use of tianeptine to psychiatrists due to its abuse potential,[27] while Bahrain has classified it a controlled substance due to increasing reports of misuse and abuse by patients.[28]

Tianeptine (under "Coaxil" brand name) has been intravenously injected by drug users in Armenia and Russia.[29][30] This method of administration reportedly causes an opioid-like effect and is sometimes used in an attempt to lessen opioid withdrawal symptoms.[29] As tianeptine tablets do not fully dissolve and often the solution is not filtered well, particles in the injected fluid can block small blood vessels, leading to thrombosis and then severe necrosis.

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

Further reading

External links

GABAA PAMs
Others
α2δ VDCC Blockers
5-HT1A Agonists
Azapirones: Buspirone • Gepirone • Tandospirone; Others: Flesinoxan • Oxaflozane
H1 Antagonists
Diphenylmethanes: Captodiame • Hydroxyzine; Others: Brompheniramine • Chlorpheniramine • Pheniramine
CRH1 Antagonists
NK2 Antagonists
MCH1 antagonists
mGluR2/3 Agonists
mGluR5 NAMs
TSPO agonists
σ1 agonists
Others

M: PSO/PSI

dsrd (o, p, m, p, a, d, s), sysi/epon, spvo

proc, drug(N5A/5B/5C/6A/6B/6D)

Acetylcholinesterases
Ampakines
CX-516 • CX-546 • CX-614 • CX-691 • CX-717 • IDRA-21 • LY-404,187 • LY-503,430 • PEPA • Sunifiram • Unifiram
D1 Agonists
Eugeroics
GABAA α5 Inverse Agonists
H3 Antagonists
mACh Agonists
nACh Agonists
Racetams
Others
Classes
Antidepressants
7-OH-Amoxapine • Amezepine • Amineptine • Amitriptyline • Amitriptylinoxide • Amoxapine • Aptazapine • Azepindole • Azipramine • Butriptyline • Cianopramine • Ciclazindol • Ciclopramine • Clomipramine • Cotriptyline • Cyanodothiepin • Demexiptiline • Depramine/Balipramine • Desipramine • Dibenzepine • Dimetacrine • Dosulepin/Dothiepin • Doxepin • Enprazepine • Esmirtazapine • Fluotracen • Hepzidine • Homopipramol • Imipramine • Imipraminoxide • Intriptyline • Iprindole • Ketipramine • Litracen • Lofepramine • Losindole • Loxapine • Maprotiline • Mariptiline • Mazindol • Melitracen • Metapramine • Mezepine • Mianserin • Mirtazapine • Naranol • Nitroxazepine • Nortriptyline • Noxiptiline • Octriptyline • Opipramol • Oxaprotiline • Pipofezine • Pirandamine • Propizepine • Protriptyline • Quinupramine • Setiptiline/Teciptiline • Tandamine • Tampramine • Tianeptine • Tienopramine • Trimipramine
Antihistamines
Antipsychotics
Acetophenazine • Amoxapine • Asenapine • Butaclamol • Butaperazine • Carphenazine • Carpipramine • Chlorpromazine • Chlorprothixene • Ciclindole • Clocapramine • Clomacran • Clotiapine • Clozapine • Flucindole • Fluotracen • Flupentixol • Fluphenazine • Gevotroline • Homopipramol • Levomepromazine/Methotrimeprazine • Loxapine • Maroxepin • Mesoridazine • Metitepine/Methiothepin • Metoxepin • Mosapramine • Naranol • Olanzapine • Perazine • Perphenazine • Periciazine • Piperacetazine • Pipotiazine • Piquindone • Prochlorperazine • Promazine • Prothipendyl • Quetiapine • Sulforidazine • Thiethylperazine • Thiopropazate • Thioridazine • Thiothixene • Trifluoperazine • Triflupromazine • Zotepine • Zuclopenthixol
Others
be:Тыянептын

de:Tianeptin fr:Tianeptine pl:Tianeptyna pt:Tianeptina

ru:Тианептин
  1. ↑ 1.0 1.1 1.2 Royer RJ, Albin H, Barrucand D, Salvadori-Failler C, Kamoun A (1988). "Pharmacokinetic and metabolic parameters of tianeptine in healthy volunteers and in populations with risk factors". Clinical Neuropharmacology. 11 Suppl 2: S90–6. PMID 3180120. 
  2. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  3. ↑ "( Stablon, Coaxil ) and the dopamine D(2) and D(3) receptors". Tianeptine. Retrieved 2010-08-13. 
  4. ↑ Kasper S, McEwen BS (2008). "Neurobiological and clinical effects of the antidepressant tianeptine". CNS Drugs. 22 (1): 15–26. doi:10.2165/00023210-200822010-00002. PMID 18072812. 
  5. ↑ 5.0 5.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  6. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  7. ↑ 7.0 7.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  8. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  9. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  10. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  11. ↑ "ISRCTN16400909 - Tianeptine for the treatment of fibromyalgia: a prospective double-blind, randomised, single-centre, placebo-controlled, parallel group study". Controlled-trials.com. Retrieved 2010-08-13. 
  12. ↑ [1][dead link]
  13. ↑ "Pharmos Corporation - Synthetic Cannabinoid Platform". Pharmoscorp.com. Retrieved 2010-08-13. 
  14. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  15. ↑ Aleksandrovskiĭ IuA, Avedisova AS, Boev IV; et al. (2005). "[Efficacy and tolerability of coaxil (tianeptine) in the therapy of posttraumatic stress disorder]". Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova (in Russian). 105 (11): 24–9. PMID 16329631. 
  16. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  17. ↑ Les Labotoires Servier (2005). "STABLON (Tianeptine) - Summary of Product Characteristics". STABLON (Tianeptine) - OVERVIEW. Servier International. Retrieved 8 October 2005. 
  18. ↑ "Google search of The National Center for Biotechnology Information website for articles containing "tianeptine" and "prenatal"". Retrieved 20 October 2005. [unreliable source?]
  19. ↑ Costa e Silva JA, Ruschel SI, Caetano D; et al. (1997). "Placebo-controlled study of tianeptine in major depressive episodes". Neuropsychobiology. 35 (1): 24–9. doi:10.1159/000119326. PMID 9018020. 
  20. ↑ (Turkish) Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  21. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  22. ↑ Les Laboratoires Servier (2009). "Stablon - Summary of Product Characteristics, March 2009". Retrieved 21 February 2010. 
  23. ↑ APM Health Europe (2007). "Addiction leads to warning on Servier's antidepressant Stablon". Retrieved 24 July 2008. 
  24. ↑ Dr. Valerie Gibaja (2006). "Use, Drug Abuse and Tianeptine (in French)" (PDF). Retrieved 24 July 2008. 
  25. ↑ The Good Drug Guide - BioPsychiatry.com (2006). "A Case of Tianeptine Abuse". Retrieved 14 March 2008. 
  26. ↑ French Health Products Safety Agency (Afssaps) (2007). "Important Information on Drug: Update of the Summary of Product Characteristics Stablon , 16 May 2007 (French)". Retrieved 24 July 2008. 
  27. ↑ World Health Organisation (2001). "Pharmaceuticals: Restrictions in use and availability, March 2001" (PDF). Retrieved 24 July 2008. 
  28. ↑ World Health Organisation (2003). "Pharmaceuticals: Restrictions in use and availability, April 2003" (PDF). Retrieved 24 July 2008. 
  29. ↑ 29.0 29.1 Richard Ives (2008). "Assessment Mission Report for the SCAD V Programme, Component on Prevention and on Media Work" (PDF). Retrieved 4 November 2008. 
  30. ↑ Flavio Mirella; et al. (2005). "Illicit Drug Trades in the Russian Federation" (PDF). Retrieved 4 November 2008. 
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Tianeptine&oldid=32271"